Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Active Tuberculosis
25%
Adjusted Odds Ratio
5%
Adverse Events
5%
Alpha Variant
14%
Asylum Seekers
5%
AY.4.2
6%
Chronic Infection
9%
Clinical Samples
8%
Clinically Significant
5%
Confirmed Cases
6%
Contact Tracing
19%
COVID-19
58%
Delta Variant
9%
Directly Observed Therapy
8%
Disease Severity
6%
Drug Susceptibility Testing
13%
During Treatment
11%
Dyspnea
11%
Embase
5%
Epidemiological Study
10%
Epidemiology
5%
Ethambutol
8%
Europe
7%
Fluoroquinolones
5%
Genetic Resistance
6%
Hospital Admission
11%
Hospitalization
7%
Incidence Rate
7%
Infectious Diseases
6%
Interferon-gamma Release Assay
8%
Latent Tuberculosis
11%
Latent Tuberculosis Infection
13%
Lessons Learned
6%
Low Incidence
12%
Low-incidence Country
5%
MEDLINE
6%
Meta-analysis
6%
Migrants
19%
Minimum Inhibitory Concentration
7%
Molecular Epidemiology
5%
Multidrug-resistant Tuberculosis (MDR-TB)
27%
Mycobacterial Interspersed Repetitive Units
14%
Mycobacterium
5%
Mycobacterium Tuberculosis (M. tb)
97%
National Institutes of Health
8%
Patient-centered
6%
Population-based Cohort Study
9%
Primary Care
5%
Prospective Cohort Study
6%
Prospective Observational Cohort Study
9%
Public Health
9%
Public Health England
5%
Public Health Management
5%
Public Health Preparedness
10%
Reinfection
8%
Retrospective Cohort Analysis
6%
Risk Factors
11%
SARS-CoV-2 Lineages
9%
SARS-CoV-2 Variants
19%
Scotland
5%
Screening Program
5%
Sequence Data
10%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
29%
Single nucleotide Polymorphism
5%
Social Risk
7%
Strain Typing
6%
Surnames
9%
Surveillance System
5%
TB Incidence
17%
Transmissibility
11%
Treatment Efficacy
7%
Treatment Outcome
6%
Tuberculin Skin Test
6%
Tuberculosis Control
10%
Tuberculosis Diagnosis
8%
Tuberculosis Outbreak
7%
Tuberculosis Risk
15%
Tuberculosis Surveillance
6%
Tuberculosis Treatment
7%
United Kingdom
17%
Variable number Tandem Repeat
14%
Variants of Concern
13%
Virus
9%
Wales
6%
Whole Genome Sequencing
31%
World Health Organization
10%
Medicine and Dentistry
Adverse Event
5%
Cohort Analysis
30%
Cohort Effect
5%
Contact Examination
18%
COVID-19
24%
Directly Observed Therapy
7%
Diseases
19%
Drug Resistance
5%
Drug Use
6%
Ethambutol
6%
Genetics
16%
Health Care Personnel
5%
Infection
7%
Interferon
5%
Interferon Gamma Release Assay
7%
Latent Tuberculosis
21%
Multidrug Resistant Tuberculosis
24%
Mycobacterium Tuberculosis
15%
Observational Study
6%
Odds Ratio
7%
Prevalence
7%
Prophylaxis
5%
Prospective Cohort Study
5%
Public Health
24%
Quinolone Derivative
5%
Release Assay
5%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Systematic Review
14%
Tandem Repeat
9%
Treatment Outcome
7%
Tuberculosis
100%
Tuberculosis Treatment
8%
Whole Genome Sequencing
23%